Short Interest in Mainz Biomed NV (NASDAQ:MYNZ) Increases By 89.5%

Mainz Biomed NV (NASDAQ:MYNZ) was the target of a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 467,577 shares, an increase of 89.5% from the February 12th total of 246,769 shares. Approximately 5.2% of the shares of the company are short sold. Based on an average daily trading volume, of 1,043,162 shares, the short-interest ratio is currently 0.4 days. Based on an average daily trading volume, of 1,043,162 shares, the short-interest ratio is currently 0.4 days. Approximately 5.2% of the shares of the company are short sold.

Hedge Funds Weigh In On Mainz Biomed

A number of hedge funds have recently modified their holdings of MYNZ. Armistice Capital LLC lifted its holdings in shares of Mainz Biomed by 96.5% during the fourth quarter. Armistice Capital LLC now owns 775,263 shares of the company’s stock valued at $868,000 after purchasing an additional 380,744 shares during the last quarter. Cerity Partners LLC acquired a new position in shares of Mainz Biomed in the 4th quarter valued at $183,000. Finally, Steward Partners Investment Advisory LLC increased its stake in Mainz Biomed by 200.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock worth $34,000 after purchasing an additional 20,000 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have weighed in on MYNZ shares. Wall Street Zen upgraded shares of Mainz Biomed to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings restated a “sell (e)” rating on shares of Mainz Biomed in a research report on Monday, December 22nd. Finally, Maxim Group lowered shares of Mainz Biomed from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce”.

Mainz Biomed Price Performance

Mainz Biomed stock remained flat at $0.84 during mid-day trading on Friday. The firm has a market cap of $7.65 million, a price-to-earnings ratio of -0.01 and a beta of 0.31. Mainz Biomed has a one year low of $0.55 and a one year high of $5.34. The business’s fifty day simple moving average is $0.97 and its two-hundred day simple moving average is $1.25. The company has a current ratio of 0.52, a quick ratio of 0.43 and a debt-to-equity ratio of 0.44.

About Mainz Biomed

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.